Study on the comparative analysis of the efficacy of transmesenteric vein extrahepatic portosystemic shunt and transjugular intrahepatic portosystemic shunt in the treatment of cavernous transformation of portal vein.
10.3760/cma.j.cn501113-20221002-00485
- Author:
Ya Dong ZHU
1
;
Wei Xiao LI
1
;
Ming Zhe CUI
1
;
Heng WANG
1
;
Hai Peng YANG
1
;
Shui Ting ZHAI
1
Author Information
1. Departent of Vascular Surgery, Henan University People's Hospital(Henan Provincial People's Hospital), Zhengzhou 450003, China.
- Publication Type:Journal Article
- Keywords:
Cavernous transformation of the portal vein;
Portal Hypertension;
Transjugular intrahepatic portosystemic shunt;
Transmesenteric vein extrahepatic portosystemicshunt
- MeSH:
Humans;
Portal Vein/surgery*;
Portasystemic Shunt, Transjugular Intrahepatic/methods*;
Hepatic Encephalopathy/etiology*;
Treatment Outcome;
Hypertension, Portal/complications*;
Retrospective Studies;
Gastrointestinal Hemorrhage/etiology*
- From:
Chinese Journal of Hepatology
2023;31(1):90-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the safety and efficacy of transmesenteric vein extrahepatic portosystemic shunt (TEPS) and transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of cavernous transformation of the portal vein (CTPV). Methods: The clinical data of CTPV patients with patency or partial patency of the superior mesenteric vein treated with TIPS or TEPS treatment in the Department of Vascular Surgery of Henan Provincial People's Hospital from January 2019 to December 2021 were selected. The differences in baseline data, surgical success rate, complication rate, incidence rate of hepatic encephalopathy, and other related indicators between TIPS and TEPS group were statistically analyzed by independent sample t-test, Mann-Whitney U test, and Chi-square test. Kaplan-Meier survival curve was used to calculate the cumulative patency rate of the shunt and the recurrence rate of postoperative portal hypertension symptoms in both groups. Results: The surgical success rate (100% vs. 65.52%), surgical complication rate (6.67% vs. 36.84%), cumulative shunt patency rate (100% vs. 70.70%), and cumulative symptom recurrence rate (0% vs. 25.71%) of the TEPS group and TIPS group were statistically significantly different (P < 0.05). The time of establishing the shunt [28 (2141) min vs. 82 (51206) min], the number of stents used [1 (12) vs. 2 (15)], and the length of the shunt [10 (912) cm vs. 16 (1220) cm] were statistically significant between the two groups (t = -3.764, -4.059, -1.765, P < 0.05). The incidence of postoperative hepatic encephalopathy in the TEPS group and TIPS group was 6.67% and 15.79% respectively, with no statistically significant difference (Fisher's exact probability method, P = 0.613). The pressure of superior mesenteric vein decreased from (29.33 ± 1.99) mmHg to (14.60 ± 2.80) mmHg in the TEPS group and from (29.68 ± 2.31) mmHg to (15.79 ± 3.01) mmHg in TIPS group after surgery, and the difference was statistically significant (t = 16.625, 15.959, P < 0.01). Conclusion: The best indication of TEPS is in CTPV patients with patency or partial patency of the superior mesenteric vein. TEPS improves the accuracy and success rate of surgery and reduces the incidence of complications.
